Kevin Pollack Net Worth

The estimated Net Worth of Kevin Pollack is at least $3.62 Thousand dollars as of 15 December 2017. Mr. Pollack owns over 108,334 units of Pressure BioSciences stock worth over $3,625 and over the last 12 years he sold PBIO stock worth over $0. In addition, he makes $0 as Independent Director at Pressure BioSciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Pollack PBIO stock SEC Form 4 insiders trading

Kevin has made over 4 trades of the Pressure BioSciences stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 108,334 units of PBIO stock worth $31,417 on 15 December 2017.

The largest trade he's ever made was buying 108,334 units of Pressure BioSciences stock on 15 December 2017 worth over $31,417. On average, Kevin trades about 3,314 units every 31 days since 2012. As of 15 December 2017 he still owns at least 131,813 units of Pressure BioSciences stock.

You can see the complete history of Mr. Pollack stock trades at the bottom of the page.

Kevin Pollack biography

Kevin A. Pollack J.D. serves as Independent Director of the Company. He has served as a director of the Company since July 2012. From 2017 to 2018, Mr. Pollack served as an advisor to Opiant Pharmaceuticals, Inc. (OPNT-NASDAQ), a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose. He previously served as its Chief Financial Officer and as a member of its Board of Directors from 2012 until 2017. He also serves as President of Short Hills Capital LLC, where he provides a range of services. Previously, Mr. Pollack worked in asset management at Paragon Capital LP, focusing primarily on U.S.-listed companies, and as an investment banker at Banc of America Securities LLC, focusing on corporate finance and mergers and acquisitions. Mr. Pollack started his career at Sidley Austin LLP (formerly Brown & Wood LLP) as a securities attorney focusing on corporate finance, and mergers and acquisitions. He currently sits on the Board of Directors of Taronis Technologies, Inc. (TRNX-NASDAQ). Mr. Pollack graduated magna cum laude from the Wharton School of the University of Pennsylvania and received a dual J.D./M.B.A. from Vanderbilt University, where he graduated with Beta Gamma Sigma honors.

How old is Kevin Pollack?

Kevin Pollack is 49, he's been the Independent Director of Pressure BioSciences since 2012. There are 7 older and no younger executives at Pressure BioSciences. The oldest executive at Pressure BioSciences, Inc. is Richard T. Schumacher, 71, who is the Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director.

What's Kevin Pollack's mailing address?

Kevin's mailing address filed with the SEC is 14 Norfolk Ave, South Easton, MA 02375, USA.

Insiders trading at Pressure BioSciences

Over the last 21 years, insiders at Pressure BioSciences have traded over $0 worth of Pressure BioSciences stock and bought 433,961 units worth $321,010 . The most active insiders traders include Gregory Gene Freitag, Richard T Schumacher, and Kevin W Quinlan. On average, Pressure BioSciences executives and independent directors trade stock every 111 days with the average trade being worth of $342. The most recent stock trade was executed by Bradford Addison Young on 31 December 2018, trading 1,579 units of PBIO stock currently worth $3,553.

What does Pressure BioSciences do?

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. It serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. Pressure BioSciences, Inc. has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts.

Complete history of Mr. Pollack stock trades at Pressure BioSciences and BBHC Inc

Pressure BioSciences executives and stock owners

Pressure BioSciences executives and other stock owners filed with the SEC include:

• Richard Schumacher,
  Director
• Richard T. Schumacher,
  Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director
• Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D.,
  Sr. VP of Engineering
• Dr. Alexander V. Lazarev,
  Chief Science Officer
• Daniel Shea,
  Chief Financial Officer
• Michael Urdea,
  Independent Director
• Kevin Pollack,
  Independent Director
• Vito Mangiardi,
  Independent Director
• Jeffery Peterson,
  Independent Chairman of the Board
• John B. Hollister,
  Director of Sales & Marketing
• Alexander V Lazarev,
  Director
• Bradford Addison Young,
  Chief Commerical Officer
• Jeffrey N Peterson,
  Director
• Richard Thomley,
  Chief Financial Officer
• Joseph Luis Jr Damasio,
  VP of Finance
• Calvin Albert Saravis,
  Director
• Matthew B Potter,
  Vice President of Sales
• Steven E Hebert,
  CFO / VP Finance / Asst. Treas
• J Donald Payne,
  Director
• Edward H Myles,
  Vice President of Finance/CFO
• Edmund Y Ting,
  Senior VP of Engineering
• Kevin W Quinlan,
  Director
• P Thomas Vogel,
  Director
• R Wayne Fritzsche,
  Director
• Alan D Rosenson,
  Director
• Nathan Lawrence,
  VP of Marketing and Sales
• Gregory Gene Freitag,
  Director
• Clayton Acss Llc/Il Struve,
  
• Alan Ira Goldberg,
  Director